Podcasts about jacc

Send a textYou read everywhere that you “should” cut salt—especially if your blood pressure is up. But salt also makes food enjoyable. In this episode, I walk through the human evidence (not animal studies) and frame salt as a risk–benefit tradeoff: when does sodium meaningfully matter, for whom, and how can you test your sensitivity?Big questions we answerIf you have high blood pressure: does lowering salt always help?If your BP is normal but you have heart/kidney risk: does salt matter?If you're basically healthy: how worried should you be?Key takeawaysSodium is essential (nerves, muscles, fluid balance)—the issue is dose and individual response.Most sodium comes from packaged/restaurant foods (not your salt shaker).Salt restriction lowers BP, but the average effect is modest compared with typical BP meds (context matters).Salt sensitivity varies: roughly ~30% of healthy people and ~40–50% of people with hypertension may be “salt-sensitive” (with higher rates in older adults, women, and some ancestry groups).If you're salt-sensitive—especially with hypertension—being mindful of sodium is likely worth it. If you're not, the “must be low-salt for everyone” story is less clear.Practical: Do an N-of-1 salt sensitivity testMeasure home BP daily (or a few times/day) for a weekGo lower-sodium for 1–2+ weeks (at least within guidelines, possibly lower)Track BP changeAdd salt back and watch what happensOptional: repeat the low-salt phase for confirmation If BP shifts meaningfully (often ~3–5 mmHg+), you may be salt-sensitive.Food reality check (why sodium adds up fast)~10% of a 2,300 mg/day sodium “budget”: 2 slices bread, 1 Tbsp ketchup, or a pinch of salt~1/3: 1 cup canned soup, 1 slice pizza, or a Big Mac~1/2: frozen lasagna, a few deli slices, or a 6” cold-cut sub Cooking mostly from whole foods makes staying lower-sodium much easier.Studies & resources mentioned (links embedded)CDC hypertension awareness/treatment/control stats: https://www.cdc.gov/nchs/products/databriefs/db511.htmHypertension outcomes review (risk of events/death): https://pmc.ncbi.nlm.nih.gov/articles/PMC8292050/Population sodium/BP overview (JACC): https://www.jacc.org/doi/10.1016/j.jacc.2019.11.055DASH-Sodium trial (NEJM): https://www.nejm.org/doi/full/10.1056/NEJM200101043440101Sodium restriction meta-analysis (BP/outcomes): https://pmc.ncbi.nlm.nih.gov/articles/PMC12624901/Salt sensitivity overview (AHA/Hypertension): https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.123.17959Heart failure trials/meta (salt restriction): https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.122.009879Salt substitute trial (NEJM): https://www.nejm.org/doi/full/10.1056/NEJMoa2105675Call to action Are you going to run your own N-of-1 salt test? If you do, I'd love to hear what you learn.Reminder: I'm an educational resource, no

Dr. Carolyn Lam and Dr. Harlan Krumholz sit down with Dr. Rishi Wadhera to unpack the first-ever JACC Cardiovascular Statistics issue. They explore why this annual report matters, the key trends in U.S. cardiovascular health, and what clinicians should take away about hypertension, diabetes, obesity, and heart‑failure patterns. The discussion highlights implementation gaps, disparities, and how data can guide action in heart health.

In this episode of JACC This Week, Dr. Carolyn Lam and Dr. Harlan Krumholz spotlight a mini-focus issue on hypertrophic cardiomyopathy (HCM), a field undergoing rapid transformation. The discussion centers on the MAPLE-HCM trial comparing aficamten and metoprolol in symptomatic obstructive HCM, highlighting multidomain response analysis and what it means to measure meaningful improvement. Beyond gradients and biomarkers, the conversation explores a critical question: when physiologic surrogates improve, how should we interpret patient-centered outcomes? Framed by the Editor's Page, "What Does Improvement Mean?", this episode examines the evolving role of myosin inhibitors, disease modification, and the tension between surrogate markers and real-world clinical benefit. Additional highlights include disaggregation of Asian ethnicities in heart failure quality-of-care research and emerging evidence on AI-driven ECG models to predict incident heart failure—underscoring JACC's commitment to precision, equity, and innovation. This issue reflects a broader shift across cardiology: transforming once-static diseases into treatable chronic conditions guided by rigorous evidence.

Commentary by Dr.  Jian'an Wang.

Commentary by Dr. Qin LU.

Commentary by Dr. Matteo Sturla

Commentary by Dr. Takeshi Aiba

Commentary by Dr.  Jian'an Wang.

Commentary by Dr.  Jian'an Wang

Commentary by Dr.  Jian'an Wang

Commentary by Dr.  Jian'an Wang

Commentary by Dr.  Jian'an Wang

Commentary by Dr.  Jian'an Wang

Commentary by Dr.  Jian'an Wang

Audio Summary of the March 2026 Issue of JACC: Asia, by Dr. Jian'an Wang.

Commentary by Dr. Yunshan Cao

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on A 4-Decade Population-Based Registry of Thoracic Aortic Dissection Causing Sudden Death in the Young.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Device-Removal, Reinfection, and Mortality After Staphylococcus aureus Bacteremia in Patients With Cardiac Implantable Electronic Devices.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Multisite, External Validation of an AI-Enabled ECG Algorithm for Detection of Low Ejection Fraction.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Increasing Awareness and Reducing Occupational Hazards in the Cardiac Catheterization and Electrophysiology Laboratories: Working to Eliminate Lead and Complications of Radiation in Cardiovascular Team Study.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Long-Term Cardiovascular Health Trajectories Associated With Cardiovascular Disease and Mortality in Older Adults.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Risk Score Development to Predict Postpartum Cardiovascular Disease Incorporating Pregnancy and Nonpregnancy Factors: A Canada-Wide Study.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Atrial Fibrillation/Flutter in Transthyretin Cardiac Amyloidosis: Prevalence, Incidence, Clinical Predictors, and Effect of Tafamidis.

Candice K. Silversides, MD, FACC, Editor-in-Chief of JACC: Advances, interviews authors Sarah Godfrey MD, MPH, FACC and Caroline L. Doherty DNP, AGACNP-BC, FACC about their paper, "Identifying Palliative Care Competencies for Cardiology Fellowship Training: A National Delphi Consensus Study" published in the February 2026 issue of the Journal.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Prognostic Value of CMR-Derived Left Ventricular Filling Pressure in Broad Referral Populations.

In this episode of JACC This Week, Dr. Carolyn Lam and Dr. Harlan Krumholz spotlight the 2025 Adult Congenital Heart Disease (ACHD) Guidelines and explore what they signal for the future of cardiovascular care. Framed by Dr. Krumholz's Editor's Page, "From Survival to Stewardship," this discussion highlights a broader transformation in cardiology: advances that once turned fatal conditions into survivable ones now demand lifelong, structured, and hyper-specialized care. The conversation examines how ACHD exemplifies the shift from episodic survival to coordinated stewardship—where surveillance, systems design, and scalable expertise are essential. The episode also reviews key updates from the guidelines, including risk-based classification, lifelong monitoring, ACHD center collaboration, and global and early-career perspectives. Additional highlights from the issue include cardiac screening in the young, cardio-renal trial insights from CONFIDENCE, wildfire-related cardiovascular risk, and emerging cardiometabolic intersections. This mini-spotlight issue challenges clinicians to rethink how specialized cardiovascular care can be delivered effectively at scale.

In this episode of JACC This Week, Dr. Carolyn Lam and Dr. Harlan Krumholz explore the JACC Women's Cardiovascular Health Issue—an edition dedicated to advancing science, care, and professional culture for women in cardiology. The discussion spans original research and viewpoints addressing menopause and cardio-oncology risk, sex differences in dilated cardiomyopathy, device trials, rehabilitation after heart failure, global disparities, and the intersection of sex, race, and socioeconomic status in cardiovascular outcomes. Beyond inclusion, this episode highlights a deeper challenge: whether our systems of evidence generation, clinical care, and professional training are designed to serve women fully and routinely. The conversation also features a powerful viewpoint by Sarah Krumholz, Dueling Pursuits: Balancing Motherhood and Medicine, catalyzing a broader dialogue about leadership gaps, culture, and the future of cardiology. This episode sets the stage for a special bonus continuation focused on redesigning the profession for the next generation.

This bonus episode continues the conversation from the JACC Women's Cardiovascular Health Issue, moving from science to systems. In this extended discussion, Drs. Carolyn Lam and Harlan Krumholz are joined by Sarah Krumholz to reflect on how the culture and structure of cardiology shape the experiences of women in training and practice.

This study analyzes over 2,600 transthyretin V142I variant carriers in the Million Veteran Program and finds significantly elevated risks of heart failure, cardiomyopathy, arrhythmias, neuropathy, and musculoskeletal complications compared with matched controls. Despite these risks, amyloidosis was rarely diagnosed clinically, underscoring major gaps in recognition and the need for earlier identification and multidisciplinary intervention.

JACC: CardioOncology Volume 8 Issue 1 Full Issue Summary with Introduction by Dr. Bonnie Ky, Editor-in-Chief

Researchers used genome‑wide CRISPR/Cas9 loss‑of‑function screens in cardiomyocytes to identify RARA and SPNS1 as key modulators of doxorubicin cardiotoxicity, highlighting pathways that influence both injury susceptibility and intracellular drug handling. Activation of RARA reduced toxicity without impairing anticancer effects, while SPNS1 loss caused harmful drug accumulation, offering new mechanistic insights and potential therapeutic targets.

This study of 801 multiple myeloma patients found that atrial fibrillation occurred in 5.5% within 90 days after autologous stem cell transplantation—nearly double previously reported rates—indicating disease‑specific risks. AF strongly predicted mortality from non‑relapse causes and may serve as a marker of physiological vulnerability, emphasizing the value of expanded pre‑transplant cardiac assessment and monitoring.

Polygenic risk scores showed associations with several cardiometabolic outcomes in breast cancer survivors but did not improve prediction beyond traditional clinical factors. Their performance varied across ancestry groups and was weakened in patients exposed to cardiotoxic therapies, highlighting limits of current genetic risk tools.

Mirza Umair Khalid, MD, Social Media Editor for JACC: Cardiovascular Interventions, and Rikke Sørensen, MD, PhD, discuss a recently published original research paper from DanGer Shock substudy analyzing the bleeding events in patients with infarct related cardiogenic shock.

Mirza Umair Khalid, MD, Social Media Editor for JACC: Cardiovascular Interventions, and Mattio Galli, MD, PhD, discuss a recently published original research paper analyzing the role of genotype-guided escalation or de-escalation of antiplatelet therapy in acute coronary syndrome (ACS).

In this episode of JACC This Week, Dr. Harlan M. Krumholz and Dr. Carolyn S.P. Lam discuss a dedicated issue of JACC focused on cardiac amyloidosis—one of the fastest-evolving areas in cardiovascular medicine. They explore new evidence highlighting significant delays in diagnosing ATTR cardiomyopathy, the early divergence of mortality benefit with timely treatment, and why time to diagnosis is no longer a neutral factor. The conversation also examines secondary analyses from major clinical trials, practical guidance for amyloidosis evaluation and management, and Dr. Krumholz's Editor's Page on "computable diagnosis" as a moral imperative. This episode places emerging science in clinical context, emphasizing urgency, equity, and how clinicians should be thinking differently about diagnosis, staging, and access to therapy in amyloid heart disease. Read Full issue here: https://www.jacc.org/toc/jacc/87/5 Keywords: cardiac amyloidosis, amyloid heart disease, ATTR cardiomyopathy, computable diagnosis

Commentary by Dr.  Jian'an Wang.

Commentary by Dr.  Jian'an Wang.

Commentary by Dr.  Jian'an Wang.

Commentary by Dr.  Jian'an Wang.

Commentary by Dr.  Jian'an Wang.

Commentary by Dr.  Jian'an Wang.

Welcome to the new season of JACC This Week! In this episode, Editor-in-Chief Dr. Harlan Krumholz is joined by co-host Dr. Carolyn Lam to kick off a refreshed, more conversational era of the podcast. Together, they reflect on the evolution of the show, approach to thematic curation, and introduce the February 3 issue of JACC, curated around valve heart disease. The discussion explores JACC's approach to thematic issues, the importance of timely publication, and how emerging evidence is shifting valvular heart disease management toward lifetime decision-making and patient-centered outcomes. Highlights include insights into aortic stenosis and regurgitation, tricuspid regurgitation, global perspectives on valve care, and what clinicians should be watching as transcatheter therapies continue to evolve. Dr. Krumholz also shares the thinking behind his Editor's Page on scientific writing—specifically, how a strong introduction earns the reader's trust—offering practical guidance for researchers at all stages. The episode sets the tone for a new season focused on rigor, relevance, global inclusion, and meaningful dialogue with the cardiovascular community.

Commentary by Dr.  Thomas Zegkos.

Commentary by Dr.  Chhabi Satpathy.

Mirza Umair Khalid, MD, social media editor of JACC: Cardiovascular Interventions, and Dr. Rebecca Hahn, MD discuss a recently published study examining new onset conduction disturbances after TTVR.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Association Between Air Pollution and Monday Peak Mortality From Acute Myocardial Infarction.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Association of Pulmonary Artery Compliance and Adverse Cardiac Events.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on The Association Between Office, Video, and Telemanagement Encounters and GDMT Optimization in Advanced HFrEF.

Peripheral artery disease has been called the ‘silent circulatory crisis'—affecting millions, limiting mobility, and quietly raising the risk of heart attack, stroke, and limb loss. For decades, treatment focused on walking programs, aspirin, and sometimes a stent or bypass. But today, the landscape is changing. From PCSK9 inhibitors that drive cholesterol to record lows, to GLP-1 agonists like semaglutide improving walking distance, to novel antithrombotic strategies that balance bleeding and clotting—PAD care is entering a new era. In this episode, we'll explore the breakthroughs, the evidence behind them, and what they mean for patients who just want to keep moving forward." Hosted by the University of Michigan Department of Vascular Surgery: - Robert Beaulieu, Program Director - Frank Davis, Assistant Professor of Surgery - Luciano Delbono, PGY-5 House Officer - Andrew Huang, PGY-4 House Officer - Carolyn Judge, PGY-2 House Officer Learning objectives:  1.  Describe the current evidence-based recommendations for multifactorial medical management of peripheral artery disease (PAD), including lipid, glycemic, and antithrombotic strategies per 2024 SVS/AHA guidelines.  2. Interpret the clinical implications of the FOURIER trial regarding the role of PCSK9 inhibition in reducing cardiovascular events in patients with atherosclerotic disease, including PAD.  3.  Evaluate the emerging role of GLP-1 receptor agonists, such as semaglutide, in improving walking performance and quality of life among patients with diabetic PAD based on findings from the STRIDE trial. Sponsor URL: https://www.goremedical.com/ References:  H. L. Gornik et al., “2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease,” JACC, vol. 83, no. 24, pp. 2497–2604, June 2024, doi: 10.1016/j.jacc.2024.02.013. L. Mazzolai et al., “2024 ESC Guidelines for the management of peripheral arterial and aortic diseases: Developed by the task force on the management of peripheral arterial and aortic diseases of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN), and the European Society of Vascular Medicine (ESVM),” Eur Heart J, vol. 45, no. 36, pp. 3538–3700, Sept. 2024, doi: 10.1093/eurheartj/ehae179. https://pubmed.ncbi.nlm.nih.gov/40169145/ M. S. Sabatine et al., “Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease,” N Engl J Med, vol. 376, no. 18, pp. 1713–1722, May 2017, doi: 10.1056/NEJMoa1615664. https://pubmed.ncbi.nlm.nih.gov/28304224/ M. P. Bonaca et al., “Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial,” Lancet, vol. 405, no. 10489, pp. 1580–1593, May 2025, doi: 10.1016/S0140-6736(25)00509-4. https://pubmed.ncbi.nlm.nih.gov/40169145/ N. E. Hubbard, D. Lim, and K. L. Erickson, “Beef tallow increases the potency of conjugated linoleic acid in the reduction of mouse mammary tumor metastasis,” J Nutr, vol. 136, no. 1, pp. 88–93, Jan. 2006, doi: 10.1093/jn/136.1.88. https://pubmed.ncbi.nlm.nih.gov/16365064/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US